Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Neoadjuvant Bevacizumab in Advanced Ovarian Cancer
NCT01847677Phase 2Terminated
- Sponsor
- Grupo Español de Investigación en Cáncer de Ovario
- Start
- May 2013
- Primary completion
- Jun 2015
- Modality
- Monoclonal Antibodies
- Countries
- 1
01
Overview
A Phase 2 trial of bevacizumab in ovarian cancer, primary peritoneal carcinoma (PPC), fallopian tube carcinoma (PFTC), sponsored by Grupo Español de Investigación en Cáncer de Ovario. Started May 2013; status: terminated.
02
Drugs
bevacizumab
03
Conditions
ovarian cancerprimary peritoneal carcinoma (PPC)fallopian tube carcinoma (PFTC)
Beyond the preview
Go deeper on NCT01847677.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT01847677.